Detect Early. Save Lives.
Cizzle Biotechnology plc
Cizzle is a UK based developer of a blood test for the early detection of a majority of different forms of lung cancer
The 7th LUCE REPORT ON LUNG CANCER, titled: Challenges in the care pathway and preferences of people with lung cancer in Europe’, highlighted two key calls to actions:
One:
Implement rapid referral pathways to reduce the time between diagnosis and treatment for people with suspected lung cancer.
National programs should be implemented to organize access to coordinated and comprehensive diagnostic services. This pathway needs to be focused on the milestones of the diagnostic process and ensure rapid access to diagnostic pathways and specialists.
Two:
领英推荐
Develop targeted screening programs to aid in the earlier diagnosis of lung cancer.
We urge everyone in the lung cancer community to come together to lobby for lung cancer screening to be included in the EU Council Recommendation on Cancer Screening, and in parallel work collectively to promote education and awareness of lung cancer screening across Europe. Now it is more important than ever as the Europe′s Beating Cancer Plan has committed the European Commission to update their recommendations on cancer screening.
This message was endorsed shortly afterwards through the Council of the EU’s recommendation to adopt a new recommendation on cancer screening to bring down mortality and incidence of invasive cancers. Previously, the cancer screening recommendation was limited to breast, cervical and colorectal cancer but has now been broadened and Member States should now explore the feasibility and effectiveness of screening with the use of low dose computed tomography (LDCT) and give special attention to the identification and targeting of high-risk profiles.?
In addition to LCDT, we believe the availability of complimentary blood tests could increase screening capability and early diagnosis. Diagnosing cancer at its earliest stage enables a greater range of treatment options, improving long-term survival rates and quality of life.
We have developed a simple blood test that can measure the presence of a biomarker highly associated with Stage 1 lung cancer and can provide an additional tool in the clinicians’ arsenal to detect lung cancer.?